Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease (Q32077293)

6 July 2017

1 reference

title

Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease (English)

1 reference

6 July 2017

0 references

1 reference

Coyle J

1

1 reference

PubMed ID

11230880

6 July 2017

Kershaw P

series ordinal

2

1 reference

PubMed ID

11230880

6 July 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

6 July 2017

Biological Psychiatry

1 reference

6 July 2017

49

1 reference

6 July 2017

289-299

1 reference

6 July 2017

3

1 reference

Choline and selective antagonists identify two subtypes of nicotinic acetylcholine receptors that modulate GABA release from CA1 interneurons in rat hippocampal slices.

6 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Survival in Alzheimer's disease and vascular dementias.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

The cholinergic hypothesis of geriatric memory dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Effectiveness of rivastigmine in Alzheimer's disease. Improvements in functional ability remain unestablished

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Time until institutionalization and death in patients with dementia. Role of caregiver training and risk factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Alzheimer's Disease: A Disorder of Cortical Cholinergic Innervation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Cholinesterase inhibitors: A new class of psychotropic compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Challenging the cholinergic hypothesis in Alzheimer disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Cholinergic markers in elderly patients with early signs of Alzheimer disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

The US economic and social costs of Alzheimer's disease revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Functional disability in Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Consensus statement on the upcoming crisis in geriatric mental health: research agenda for the next 2 decades

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Nicotinic acetylcholine involvement in cognitive function in animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Galantamine: additional benefits to patients with Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Influence of kinetics of nicotine administration on tolerance development and receptor levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. American Academy of Neurology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

A new rating scale for Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Nicotinic Stimulation of [3H]Acetylcholine Release from Mouse Cerebral Cortical Synaptosomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Economic considerations in the treatment and management of Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Effects of different doses of galanthamine, a long-acting acetylcholinesterase inhibitor, on memory in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Galanthamine, an acetylcholinesterase inhibitor: a time course of the effects on performance and neurochemical parameters in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Behavioral disturbance, cognitive dysfunction, and functional skill. Prevalence and relationship in Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

In vitro effects of various cholinesterase inhibitors on acetyl- and butyrylcholinesterase of healthy volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Are two antidepressant mechanisms better than one?

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2901101-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-3223(00)01101-X

1 reference

6 July 2017

1 reference

PubMed ID

11230880